Autoimmune complications of immunotherapy: pathophysiology and management
This review describes the clinical characteristics of immune related adverse events associated with immune checkpoint inhibitors, their pathophysiology, relationship to cancer survival, and general approaches to management.
Source:
British Medical Journal
SPS commentary:
Immune checkpoint inhibitors are monoclonal antibodies that block inhibitory molecules, such as cytotoxic T-lymphocyte-associated protein 4 (ipilimumab), programmed cell death protein 1 (nivolumab, pembrolizumab, cemiplimab), or its ligand programmed cell death protein ligand 1 (atezolizumab, avelumab, durvalumab), which leads to immune cell activation in the tumour microenvironment.